Previous analyses of adjuvant studies of aromatase inhibitors versus tamoxifen, including the Breast International Group (BIG) 1-98 study, have suggested a small numerical excess of cardiac adverse events (AEs) on aromatase inhibitors, a reduction in the incidence of hypercholesterolemia on tamoxifen, and significantly higher incidence of thromboembolic AEs on tamoxifen. The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98.
INTRODUCTION
Several third-generation aromatase inhibitors have become accepted as standard care in the adjuvant systemic therapy of postmenopausal women with endocrine-responsive early breast cancer 1,2 based on superior disease-free survival in several large clinical trials of anastrozole, [3] [4] [5] [6] exemestane, 7 and letrozole. 8, 9 The Breast International Group (BIG) study 1-98 is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole versus sequences of 2 years of one of these agents followed by 3 years of the other. In the initial report of BIG 1-98, we noted an increased number of thromboembolic adverse events (AEs) in patients receiving tamoxifen and a small increase in some types and grades of cardiac events in patients receiving letrozole. Serum cholesterol decreased on average after initiation of tamoxifen therapy, whereas it remained relatively unchanged on letrozole. Elevations of serum cholesterol, mainly low grade, were reported more frequently among patients receiving letrozole. The present report analyzes these AEs in more detail based on further follow-up and medical review of grade 3 to 5 AEs and examines the relationship between serum cholesterol elevation and cardiac AEs.
PATIENTS AND METHODS
The primary core analysis (PCA) of BIG 9 was based on 8,010 patients (after excluding 18 patients who withdrew consent and did not start treatment). The present safety analysis excluded 47 further patients who never received trial treatment and is based on data received as of April 15, 2005 , from the 7,963 patients included in the safety portion of the PCA. As in the PCA, AEs and follow-up were included up to 30 days after therapy completion or after switch on the sequential arms. The trial included two random assignment options. From March 1998 to March 2000, patients were randomly assigned to the two-arm option of monotherapy with letrozole (2.5 mg daily) or tamoxifen (20 mg daily); from April 1999 to May 2003, patients were randomly assigned to the four-arm option, which involved monotherapy with letrozole or tamoxifen or the sequential administration of tamoxifen followed by letrozole or letrozole followed by tamoxifen. The trial was stratified according to the participating center and according to whether chemotherapy was neither administered nor planned, was completed before random assignment, or was planned to be administered concurrently with endocrine therapy. The latter two strata have been combined into one group for this report (chemotherapy, yes).
Cardiovascular AEs
Specifically requested cardiovascular AEs were listed with check boxes on the case report forms. These included cardiac-ischemia/infarction, cerebrovascular accident (CVA)/transient ischemic event or attack (TIA), angina requiring percutaneous transluminal coronary angioplasty or requiring coronary bypass graft, thrombosis/embolism, hypercholesterolemia, and other cardiovascular event. Other cardiovascular AEs were also requested but were listed with a comment field for specification by the investigator. These other cardiovascular AEs were coded according to MedDRA, and MedDRA preferred term 10 codes were further grouped by International Breast Cancer Study Group oncologists into the categories presented in the PCA safety analyses. All grade 3, 4, and 5 cardiovascular AEs were medically reviewed by senior oncologists (M.R. and M.C.-G.) at the International Breast Cancer Study Group Coordinating Center. All pre-existing cardiovascular morbidities reported at baseline (and specified via a comment field) were also medically reviewed and grouped into the categories presented in the PCA safety analyses. All reviewers were blinded to randomized treatment.
Three types of analyses were conducted to look in-depth at cardiovascular safety; the first analysis focused on cardiovascular AEs, the second one looked at lipid levels, and the third one investigated the association between cardiac AEs and presence of hypercholesterolemia at baseline or at any time before the outcome AE. In the analysis of cardiovascular AEs, the following eight end points were examined: any cardiac AE, ischemic heart disease, cardiac failure, hypertension, CVA/TIA, thromboembolic AE (including deep vein thrombosis and phlebitis), peripheral atherosclerosis (including aneurysm, aortic aneurysm rupture, aortic dilation, arteriosclerosis, atherosclerosis obliterans, femoral arterial stenosis, hypertensive angiopathy, iliac artery stenosis, and intermittent claudication), and other cardiovascular AE (including any not otherwise specified cardiovascular disorder, aortic stenosis, varicose veins, venous insufficiency, ischemic colitis, vasodilation, and venous stenosis).
To compare the incidence of cardiovascular end points between treatments, two-sided Fisher's exact tests 11 were used. Time from random assignment to the first report of cardiovascular end points was compared via a log-rank test 12 stratified by random assignment option (two-arm or fourarm option) and chemotherapy (yes or no, based on chemotherapy stratum), and Kaplan-Meier 13 plots were generated. These analyses were not generated for peripheral atherosclerotic or other cardiovascular AEs because the data were sparse.
Hypercholesterolemia
In all analyses, hypercholesterolemia was considered present if either the total cholesterol levels (mg/dL) were greater than the upper limit of normal reported in the case report form or the investigator had indicated hypercholesterolemia as a pre-existing morbidity at baseline or it was reported anytime as an AE. Box plots 14 of the percent change from baseline in total cholesterol level included only patients who had baseline measurements taken and at least one follow-up measurement. Analyses of cholesterol combined fasting and nonfasting levels, although 90.9% of all recorded values were nonfasting.
Association Between Cardiac AEs and Hypercholesterolemia
To examine the association between cardiac AEs and total cholesterol levels, Cox proportional hazards models 15 were generated for time to first cardiac AE using randomized treatment assignment as a single covariate. Cox models were further adjusted for whether or not the patient had hypercholesterolemia before the outcome AE (as a time-varying covariate counted if hypercholesterolemia was present at at least one follow-up visit before the AE) and clinically relevant baseline covariates (full model), which were age at random assignment (Ն 55 v Ͻ 55 years), smoking status (ever v never smoker), body mass index (BMI; Ն 30 v Ͻ 30 kg/m 2 ), presence of hypertension (defined as systolic blood pressure Ͼ 160 mmHg or diastolic blood pressure Ͼ 90 mmHg) at baseline, presence of diabetes at baseline, and presence of cardiac morbidity at baseline. If more than 1% of patients had a missing value for a particular covariate, an indicator for whether or not the covariate was missing was included in the Cox models. Cox models were also generated for the other cardiovascular end points (excluding peripheral atherosclerotic or other cardiovascular AEs) to control for clinically relevant baseline covariates (full model). Models for time to hypertension, CVA/TIA, and thromboembolic AE were not adjusted for presence of prior hypercholesterolemia. All Cox models were stratified by random assignment option and chemotherapy.
Analyses of AEs were conducted for any grade AEs (ie, grades 1 to 5) and also restricted to AEs of grade 3 or higher. Grading of AEs was based on National Cancer Institute Common Toxicity Criteria, version 2.0. 16 The ethics committees and required health authorities of each participating institution approved the study protocol, and all patients gave written informed consent.
RESULTS
The median follow-up time for this analysis was 30.1 months. As expected from this large randomized trial, baseline patient and disease characteristics, including medical history of morbidities, were well balanced (Յ 1% difference) between treatments (Table 1) . Table 2 lists the incidence of AEs by type separately for AEs of any grade and for grades 3 to 5 only. Overall, the incidence of cardiovascular events was low in both treatment arms. Tamoxifen was associated with significantly more thromboembolic AEs, whereas letrozole was associated with significantly more peripheral atherosclerotic AEs and other cardiovascular AEs of any grade. An unplanned analysis of grade 3 to 5 AEs (severe, life threatening, or fatal) noted that tamoxifen resulted in significantly more grade 3 to 5 thromboembolic AEs and letrozole resulted in significantly more grade 3 to 5 cardiac AEs of any type and, specifically, in more such events classified as cardiac failure.
Cardiovascular AEs

Hypercholesterolemia
A total of 7,544 patients had at least one cholesterol measurement reported, and 6,446 patients had cholesterol measurements reported at baseline and at at least one follow-up visit. Most measurements (90.9%) were reported as nonfasting. Figure 1A shows box plots for 
total cholesterol by follow-up visit, and Figure 1B shows box plots for the percent change in total cholesterol from baseline by follow-up visit. Figure 1 is descriptive in nature, and its validity is to be verified by other data. Median total cholesterol decreased over time under both treatments. The decrease was greater for patients receiving tamoxifen, for whom the lowering was immediately apparent; the decrease for patients receiving letrozole began approximately 30 months after random assignment. In a sensitivity analysis restricted to the subset of 1,773 patients with available cholesterol measurements at baseline and at each follow-up visit through 3 years after random assignment, the box plot patterns of percent change in cholesterol were strikingly similar to that seen in Figure 1B . Although both letrozole and tamoxifen lowered median cholesterol levels, at each follow-up visit, a greater proportion of patients receiving letrozole had an increase in total cholesterol compared with baseline (at each follow-up visit, the box for the letrozole group crosses 0, whereas the box for the tamoxifen group is almost entirely at or below 0). This pattern explainstherelativelyhigherproportionofpatientsonletrozoleforwhom low-grade hypercholesterolemia was reported in the PCA. 9 The relationship between total cholesterol grade at baseline and grade during follow-up is shown in Appendix Table A1 (online only). Table 3 lists the results for treatment using univariate (treatment alone) and multivariate (full model) Cox models generated for time to AEs of any grade. The results were consistent with those found in univariate analyses of incidence. Even after controlling for clinically relevant covariates, tamoxifen resulted in significantly more thromboembolic AEs than letrozole. Table 4 lists the results for treatment using univariate (treatment alone) and multivariate (full model) Cox models generated 
Time to AE Analyses
‫ء‬
Hazard ratio values Ͻ 1.00 indicate a lower risk of the outcome adverse event for letrozole compared with tamoxifen. ‫ء‬ for time to grade 3 to 5 AEs. Again, the results were consistent with the univariate analyses of incidence, with significantly more grade 3 to 5 cardiac events and, specifically, grade 3 to 5 cardiac failure on letrozole and significantly more grade 3 to 5 thromboembolic events on tamoxifen. Age Ն 55 years at random assignment was a significant predictor of risk in all models, as was having a prior history of the AE being modeled. Whether or not a patient ever smoked did not significantly alter risk in any of the multivariate models. History of hypertension was a significant predictor of ischemic heart disease, CVA/TIA, hypertension, and thromboembolism. BMI was a significant predictor of hypertension only. History of diabetes was a significant predictor of any cardiac AE, particularly ischemic heart disease, and also of CVA/TIA. Presence of hypercholesterolemia before the outcome AE was a significant predictive factor for any cardiac AE and particularly for ischemic heart disease. Results for the Cox models with grade 3 to 5 AEs only were similar, with the following differences: age was not a significant predictor of ischemic heart disease; BMI was a significant predictor of cardiac failure and thromboembolism in addition to hypertension; history of diabetes was a significant predictor of cardiac failure and CVA/TIA only; and history of hypertension was a significant predictor of any grade 3 to 5 cardiac AEs, particularly ischemic heart disease, and of CVA/TIA but not of grade 3 to 5 hypertension. The direction of the effect of the covariates on risk of the AEs modeled was generally as expected, with the exception of the association of history of hypertension with decreased hypertension AE (any grade) and BMI Ն 30 kg/m 2 with decreased risk of a thromboembolic AE (grades 3 to 5). Additional results are shown in Appendix Tables A2 and A3, and Figures A1 and A2 (online only) .
Association Between Cardiac AEs and Hypercholesterolemia
As noted earlier, incidence of prior hypercholesterolemia was a significant predictor of any grade and of grade 3 to 5 cardiac AEs, including ischemic heart disease, but was associated with a nonsignificant decrease in risk of grade 3 to 5 cardiac failure. Even after controlling for incidence of prior hypercholesterolemia, letrozole was associated with a significantly increased residual risk of grade 3 to 5 cardiac AE, as seen in Table 4 .
As shown in Figure 2 , the incidence patterns for any grade cardiac AEs were quite similar between the two treatments up to 3 years after random assignment. When restricted to patients with a grade 3 to 5 AE at all time points, a greater proportion of patients receiving letrozole had an event and prior hypercholesterolemia compared with patients receiving tamoxifen. Up to 3 years after random assignment, a similar proportion of patients on the two treatments had a cardiac AE but no prior hypercholesterolemia; after 3 years, more patients on letrozole had a cardiac AE without prior hypercholesterolemia. The results shown in Figure 2 are descriptive in nature. Letrozole was associated with slightly greater incidence of grades 1 to 5 vascular AEs classified as peripheral atherosclerotic disease and with the residue of unclassified cardiovascular AEs, but in neither case did the association extend to grade 3 to 5 AEs (Table 2) . 
DISCUSSION
The higher incidence of thromboembolic disease observed on tamoxifen in BIG 1-98 is consistent with the pattern of toxicity seen in other trials comparing tamoxifen with a third-generation aromatase inhibitor. 3, 7 Although the overall incidence was low, patients at risk for thromboembolic disease, such as those with an antecedent history of such episodes, might consider avoiding adjuvant tamoxifen therapy.
We agree with Howell and Cuzick 17 that because most women now presenting with early breast cancer can expect long-term survival and vascular disease is the major cause of death in women, assessment of vascular adverse effects of highly effective adjuvant therapies such as aromatase inhibitors is important. Each of the major trials comparing a third-generation aromatase inhibitor with tamoxifen has reported a small numeric excess of cardiovascular events on the aromatase inhibitor arm, although this was not statistically significant in any of the studies. BIG 1-98 and the Arimidex (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial 3 are the largest reported randomized trials comparing initial use of an aromatase inhibitor with tamoxifen. As distinct from the ATAC trial in which prespecified checklists were not used 18 and from which grades of cardiac toxicity have not been reported, in the BIG 1-98 study, cardiovascular AEs and serum cholesterol were explicitly collected on data forms and graded according to National Cancer Institute Common Toxicity Criteria. 16 Therefore, detailed comparison between the two studies is not possible. The large ongoing phase III trial comparing anastrozole with letrozole will provide detailed head-to-head safety evaluations of those two compounds. Despite our rigorous approach, the overall reported incidence of cardiac AEs in BIG 1-98 was low on both arms and did not differ between treatments. However, in a nonplanned secondary analysis, significantly more grades 3 to 5 cardiac AEs were seen with letrozole than with tamoxifen in BIG 1-98 (Table 2) . No corresponding analysis has been published from the ATAC trial.
In BIG 1-98, median total cholesterol decreased over time on both treatments. Descriptive analyses suggested that the decrease was greater and earlier for patients receiving tamoxifen. The decrease for patients receiving letrozole began approximately 30 months after random assignment. This finding is consistent with the effect of anastrozole in the ATAC trial. 18 Prior elevation of cholesterol was associated with the subsequent recording of a grade 3 to 5 cardiac AE, but this association did not completely explain the higher incidence of cardiac AEs on letrozole. The reason for the residual effect is not clear. A possible mechanism may relate to a direct effect of profoundly lowered circulating estrogen levels on vascular endothelium, 17, [19] [20] [21] although no similar effect was observed in the placebo-controlled MA.17 trial, 8 suggesting that the difference could also reflect some protective effect of tamoxifen in BIG 1-98.
Taken together, cardiovascular AEs were relatively rare in our study, and any excess of cardiac events on letrozole seems to be outweighed by the superior control of locoregional and distant recurrence afforded by letrozole compared with tamoxifen. Nevertheless, an understanding of the nature, frequency, and mechanism of such AEs is important to optimize the therapeutic ratio in adjuvant endocrine therapy with aromatase inhibitors for postmenopausal patients with endocrine-responsive early breast cancer.
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